Abnova (Taiwan) Corporation. Share Price Taipei Exchange
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- TWD | - |
09/05 | Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
08/05 | Abnova Corporation Announces Establishment of Risk Management Committee | CI |
Sales 2022 | 41Cr 1.28Cr 106.09Cr | Sales 2023 | 38Cr 1.19Cr 98Cr | Capitalization | 212.54Cr 6.59Cr 547.64Cr |
---|---|---|---|---|---|
Net income 2022 | 7.4Cr 22.96L 19Cr | Net income 2023 | 4.3Cr 13.34L 11Cr | EV / Sales 2022 | 5.2 x |
Net cash position 2022 | 36Cr 1.1Cr 92Cr | Net cash position 2023 | 42Cr 1.29Cr 107.02Cr | EV / Sales 2023 | 4.48 x |
P/E ratio 2022 |
33.5
x | P/E ratio 2023 |
48.8
x | Employees | - |
Yield 2022 |
1.94% | Yield 2023 |
2.05% | Free-Float | 73.71% |
Managers | Title | Age | Since |
---|---|---|---|
Pei Ju Jih
CEO | Chief Executive Officer | - | 01/18/01 |
Wilber Huang
CHM | Chairman | 58 | - |
I Ling Tung
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yueh Hung Chen
BRD | Director/Board Member | 60 | 19/20/19 |
Wilber Huang
CHM | Chairman | 58 | - |
Jia Hsie Lin
BRD | Director/Board Member | 73 | 23/17/23 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-1.69% | 2.18TCr | |
-10.60% | 1.81TCr | |
-41.25% | 1.67TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |